|Awarded On||February 16, 2022|
|Title||Therapeutic approaches for TGF-beta-enriched minimal residual disease in patients with colorectal cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Van Morris|
For patients with colorectal cancer treated with curative intention using surgery (with or without chemotherapy) microscopic areas of cancer may still remain and release their DNA into the bloodstream. When detected during a blood test, this circulating tumor DNA (ctDNA) can accurately forecast an eventual return of the cancer. Alternatively, if ctDNA is not detected, the colorectal cancer will likely not return. At this time, it is unknown if patients with detectable ctDNA benefit from receiving chemotherapy, or if small, incurable metastases which have already developed.
In this proposal, our team seeks to understand better the biology that uniquely defines these microscopic tumor depo...